
Sign up to save your podcasts
Or


Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
By Medscape4.3
2525 ratings
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624

135 Listeners

694 Listeners

496 Listeners

170 Listeners

101 Listeners

885 Listeners

13 Listeners

17 Listeners

291 Listeners

260 Listeners

3,331 Listeners

1,153 Listeners

195 Listeners

90 Listeners

514 Listeners

365 Listeners

172 Listeners

61 Listeners

8 Listeners

433 Listeners